Lakefront Biotherapeutics NV (ETR:GXE)

Market Cap	1.76B +11.7%
Revenue (ttm)	1.04B +262.2%
Net Income	488.78M
EPS	7.42
Shares Out	n/a
PE Ratio	3.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11
Open	26.72
Previous Close	26.80
Day's Range	26.70 - 26.72
52-Week Range	22.84 - 32.24
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About ETR:GXE

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 704
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GXE

Financial Performance

In 2025, ETR:GXE's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 10, 2026

Data Sources Report a data error